Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

06/22/2021 | 04:21pm EDT

ZURICH, June 22 (Reuters) - Novartis aims to help manufacture more than 50 million doses of BioNTech's COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant. (Reporting by John Miller Editing by Chris Reese)


ę Reuters 2021
All news about NOVARTIS AG
07:37aBAUSCH HEALTH : Reports Q2 Revenue US$2.1 Billion; Plans To Pursue An IPO of Sol..
MT
07:03aNOVARTIS : announces lift of partial clinical trial hold and plans to initiate a..
PU
06:46aNovartis Gets FDA Approval to Proceed With Trials for Muscular Atrophy Treatm..
DJ
05:58aNOVARTIS : Says FDA Lifts Partial Hold on Clinical Trial of Spinal Muscular Atro..
MT
01:48aNOVARTIS : to Launch New Study of Neuromuscular Disease Drug After US FDA Lifts ..
MT
01:15aPRESS RELEASE : Novartis announces lift of partial -2-
DJ
01:15aPRESS RELEASE : Novartis announces lift of partial clinical trial hold and plans..
DJ
01:15aNovartis announces lift of partial clinical trial hold and plans to initiate ..
DJ
08/02IONIS PHARMACEUTICALS : Says Phase 3 Trial of Pelacarsen for Reducing Recurrent ..
MT
07/29Rubius Therapeutics Taps Dannielle Appelhans as Chief Operating Officer
DJ
More news
Financials (USD)
Sales 2021 51 982 M - -
Net income 2021 9 881 M - -
Net Debt 2021 22 970 M - -
P/E ratio 2021 20,3x
Yield 2021 3,56%
Capitalization 225 B 226 B -
EV / Sales 2021 4,77x
EV / Sales 2022 4,46x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 92,51 $
Average target price 105,60 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.14%225 528
JOHNSON & JOHNSON9.46%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.19.42%246 075
ELI LILLY AND COMPANY46.06%224 166
NOVO NORDISK A/S36.15%212 792